Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adaptimmune Awarded £2.1m from the Biomedical Catalyst Fund

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
The prestigious award supports Adaptimmune’s clinical pipeline expansion.

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.
Adaptimmune engineers patients’ T lymphocytes to target and kill cancer cells when re-infused into the body. Its approach is focused on engineering increased affinity T cell receptors (TCR), the molecules on the surface of cytotoxic T lymphocytes that are naturally designed to recognize cancer cells. The company already has one T cell receptor programme in multiple cancer trials in the USA, with promising initial results.

The funding award will be used to expedite Adaptimmune’s second clinical programme with a new TCR to enter the clinic in the UK. The award will support preclinical testing and regulatory approval for an initial pilot trial with a new TCR targeting an undisclosed protein found to be highly expressed in some forms of breast cancer and other cancer types. The trial is planned to start in 2015.

David Willetts, Minister for Universities and Science, said: “Britain has a world-leading life science cluster and Adaptimmune is a classic example of an innovative bioscience company that the Biomedical Catalyst Fund is designed to support. Its personalized therapy for cancer developed over 15 years in Oxford represents a potential breakthrough in cancer treatment for thousands of patients.”

Adaptimmune’s unique approach relies on the ability to fine-tune the affinity of the T cells to recognize the small protein fragments from intracellular cancer-specific proteins presented on the cell surface. This novel class of cancer targets cannot be bound by antibodies or chimeric antigen receptor T cells and natural affinity T cell receptors fail to bind effectively to cause a killing response. Adaptimmune has a pipeline of T cell receptors recognizing such targets and the funding award comes at a time when the company is significantly increasing its activities in the UK as well as the USA.

James Noble, Adaptimmune’s Chief Executive Officer, said: “We are delighted to be announcing the Biomedical Catalyst Fund support for our next pipeline TCR and its path towards the clinic in 2015. We have a wide portfolio of cancer targets to be exploited in this way and our objective is to develop this pipeline of TCRs as rapidly as possible for the benefit of patients.”

Dr Bent Jakobsen, Adaptimmune’s co-founder and Chief Scientific Officer, said: “The ability of T cells to track down and kill cancer cells is one of the most powerful weapons we can bring to bear on the disease. We have spent 15 years optimizing and testing T cell receptors here in the UK and the award from the Biomedical Catalyst Fund provides an important boost to expand the pipeline for the benefit of UK patients.”

Grants from the UK government-backed Biomedical Catalyst Fund totalling more than £120 million have been awarded to over 100 projects since the grant programme was introduced in 2012. The projects are led by UK-based small and medium-sized businesses and universities to accelerate the development of innovative solutions to healthcare challenges. Adaptimmune represents one of the companies which have benefitted to date from the £180 million Biomedical Catalyst fund, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. 

Adaptimmune’s existing clinical programme targets a peptide from two cancer testis antigens (CT antigens) called NY-ESO-1 and LAGE-1. Both proteins are expressed in multiple cancers and the company is running studies in the US in multiple myeloma, melanoma, synovial sarcoma and ovarian cancer, with its most recent results reported for multiple myeloma at the annual conference of the American Society of Hematology in December 2013. Details of all current clinical studies can be found on clinicaltrials.gov.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Tuesday, July 21, 2015
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Tuesday, July 21, 2015
Adaptimmune Appoints Lawrence M. Alleva to its Board of Directors
Lawrence M. Alleva will join the Board as an independent, non-executive director.
Wednesday, March 11, 2015
Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer.
Wednesday, March 04, 2015
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Friday, October 17, 2014
Adaptimmune Secures $104 Million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications.
Friday, September 26, 2014
Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
Company has created T-cell receptors which are deployed to target NY-ESO-1.
Tuesday, September 23, 2014
Adaptimmune Announces Full-time Appointment of James Noble as CEO
Appointment will become effective from 31st March.
Thursday, March 27, 2014
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells
Study continues to report encouraging response rates, safety and proof of mechanism.
Thursday, December 12, 2013
Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune announces that study continues to report encouraging response rates, safety and proof of mechanism.
Tuesday, December 10, 2013
Adaptimmune Appoints Chairman of the Board
Dr Jonathan Knowles has been appointed as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 21, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial
Adaptimmune announced that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer.
Thursday, July 25, 2013
NeoStem’s Subsidiary, PCT Enters into Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Thursday, January 24, 2013
NeoStem Subsidiary Enters Into a Cell Therapy Manufacturing Services Agreement with Adaptimmune
PCT to provide cell product development and manufacturing for Adaptimmune’s clinical trials.
Monday, January 21, 2013
Adaptimmune Announces Exclusive License with Life Technologies
The exclusive license secures a critical component for commercial development of modified T cells.
Monday, January 07, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Self-Assembling, Biomimetic Membranes May Aid Water Filtration
A synthetic membrane that self assembles and is easily produced may lead to better gas separation, water purification, drug delivery and DNA recognition, according to an international team of researchers.
Researchers Discover Immune System’s 'Trojan Horse'
Oxford University researchers have found that human cells use viruses as Trojan horses, transporting a messenger that encourages the immune system to fight the very virus that carries it.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
How Cholesterol Leads to Clogged Arteries
A new study shows that when immune cells called neutrophils are exposed to cholesterol crystals, they release large extracellular web-like structures that trigger the production of inflammatory molecules linked to artherosclerosis.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Ultrafast DNA Diagnostics
New technology developed by UC Berkeley bioengineers promises to make a workhorse lab tool cheaper, more portable and many times faster by accelerating the heating and cooling of genetic samples with the switch of a light.
Researchers Discover New Type of Mycovirus
Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!